AzTrials
AzTrials

Chronic Kidney InsufficiencyCKDODNCT03619564

Chronic Kidney Disease Observational Database - Taiwan

An observational study of Chronic Kidney Insufficiency, run by Fresenius Kabi at 9 sites in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the effect of a ketoanalogue supplemented very low protein diet on eGFR decline in chronic kidney disease compared to a low protein diet (0.6 g/kg, LPD) or no protein restriction. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Chronic Kidney Insufficiency
How many people
1,000 participants
Where
9 sitesTaiwan
Study dates
1 Aug 2018to 28 Sep 2021
How long will I take part?
2 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Primary nephrologic care

Who may be able to join

  • Age >=20 years
  • Diagnosis of chronic kidney disease stage 3b to 5 (non-dialysis) according to KDIGO1, i.e. GFR < 45 ml/min/1.73 m².
  • Regular dietetic consultancy (at least once a year) for patients with stages 4 and 5 (GFR < 30 ml/min/1.73m²) who are following a LPD or sVLPD.
  • Written informed consent according to local regulations

Who cannot join

  • Disturbed amino acid metabolism, e.g. phenylketonuria
  • A kidney transplant
  • Sustained high blood pressure (inadequately controlled (>160 mmHg systolic or >110 mmHg diastolic) despite ≥3 antihypertensive medications)
  • Independent life-threatening disease(s), i.e. terminal cancer, AIDS, stage IV heart failure, end stage liver cirrhosis
  • Renal insufficiency caused by
  • Renal cancer
Show all 9Show fewer
  • Genetic renal diseases, e.g. polycystic kidney disease, congenital nephrotic syndrome
  • Hypersensitivity to the active substances or to any of the excipients of the ketoanalogue supplement
  • Furthermore, pregnant and breast-feeding patients

Trial locations and contacts

9 sites in 1 country.

9 sites in 1 country

Taiwan9 sites
  • Hualien Tzu Chi Hospital

    Hualien City, Hualien County, 970

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Kaohsiung County, 833

  • Keelung Chang Gung Memorial Hospital

    Keelung, Keeluing City, 204;

  • Taichung Veterans General Hospital

    Taichung, Taichung City, 407

  • National Cheng Kung University Hospital

    Tainan, Tainan County, 704

  • Taipei Tzu Chi Hospital

    Taipei, New Taipei City, 231

  • Shuang Ho Hospital

    Taipei, New Taipei City, 235

  • Taipei Veterans General Hospital

    Taipei, Taipei City, 112

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, 333

Other trials in Taiwan

About this study

The purpose of this study is to determine the effect of a ketoanalogue supplemented very low protein diet on eGFR decline in chronic kidney disease compared to a low protein diet (0.6 g/kg, LPD) or no protein restriction.

Read the detailed description

An important part of care in chronic kidney disease is an adapted diet. Its most important aspect is protein restriction. The rationale for protein restriction is a reduction of uremic wastes. However, nutritional requirements for protein synthesis limit the maximum extent of protein restriction. To deal with these conflicting targets, a minimum protein intake supplemented with ketoanalogues of amino acids (supplemented very low protein diet, sVLPD) meets the protein needs while reducing uremic waste.

The aim of this explorative, observational study is to determine the effect of sVLPD on eGFR decline compared to a low protein diet (LPD) or no protein restriction.

Data collection The study uses only data from routine health care records. The transfer to the electronic case report form is done by center investigators.

Data entry is monitored monthly for completeness and plausibility. Missing or unusual data will be requested for completion or re-assessment.

In case of high loss to follow up (>10%), low follow up frequency (<90% of patients with <3 visits per year), or greater than 5% missing core data (age, gender, descent, height, weight, history of diabetes and hypertension, blood pressure, serum creatinin, dietary prescription, judgement of compliance), audit visits including source data verification and trainings may be done.

Primary analysis Direct comparison of patients receiving sVLPD or LPD is not meaningful due to the non-interventional design. It is expected that sVLPD patients will have a more advanced stage of CKD, most likely will have higher severity of disease and possibly may have different demographic baseline data. Furthermore, other well-known risk factors for progression of chronic kidney disease like the presence of diabetes mellitus or high blood pressure may affect eGFR decline.

A relevant amount of data is expected to be missing due to the observational nature and the use of data from clinical routine. Furthermore, missing data are unlikely to occur completely at random.

Therefore, missing data will not be imputed but they will be implicitly modeled by a mixed model: mean changes of eGFR from baseline will be analyzed using a restricted maximum-likelihood based repeated measures approach. Analyses will include the fixed, categorical effects of actual treatment, study center, gender, visit time, and baseline variables presence of smoking history, diabetes mellitus, hypertension, and baseline eGFR. Patient will be included as a random factor to the model. Significance tests will use a two-sided α = 0.05.

Secondary analyses Compliance, dietary counselling, use of a nutritional diary, primary diagnosis of CKD, diabetes mellitus, and vegetarian diet will be included to the model described before and analyzed for independent effects or effect modification of the diet.

The approach to the secondary analysis of development of serum urea is similar to the primary analysis.

Cox-regression analysis will be done for time to dialysis initiation or reaching the composite endpoint [>50% eGFR decline or initiation of maintenance dialysis treatment] including the same baseline variables as mentioned for the primary endpoint.

Medical subject headings
Renal Insufficiency, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03619564
Study groupRoleWhat they receive
No protein restrictionNo protein restriction
Low protein diet (LPD)LPD: < 0.8 g/kg bodyweight
Ketoanalogue suppl. very LPDsVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary composite endpoint: 50 % eGFR decline or renal replacement therapy [Time Frame: From inclusion to 2 years follow up]

    Primary composite endpoint [Time Frame: From inclusion/Patient enrolment to 2 years follow up]. Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate (eGFR) compared to time of patient inclusion into the study and after 2 years

    Measured: 2 years

Secondary outcomes (2)
  1. Prescribed diet

    Prescribed diet (no protein restriction, low protein diet, supplemented very low protein diet), 2 years

    Measured: 2 years

  2. Impact of compliance to prescribed protein diet on the eGRF decline

    Dietary compliance, 2 years, assessed by consulted dietitian (if available) estimating rated from 0 (not compliant) to 4 (fully compliant); 24 hours urine (if available, urinary urea excretion to assess the actual protein intake in comparison with the prescribed diet [normal diet, LPD, sVLPD)

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2018
  2. Study start1 Aug 2018
  3. Primary completion28 Sep 2021
  4. Study completion28 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (actual)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03619564
Sponsor's protocol ID
Keto-033-CNI
Acronym
CKDOD
Status last verified
Feb 2024
First submitted
24 Jul 2018
Last updated
22 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Kidney Insufficiency, run by Fresenius Kabi at 9 sites in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary composite endpoint: 50 % eGFR decline or renal replacement therapy [Time Frame: From inclusion to 2 years follow up] (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024; AzTrials last refreshed its copy on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in